Aleix Prat, MD, PhD, on HER2-Positive Breast Cancer: First Results of the PAMELA Trial (Spanish Language Version) 
2016 San Antonio Breast Cancer SymposiumAleix Prat, MD, PhD, of the University of Barcelona, discusses in Spanish study findings on intrinsic subtype as a predictor of pathologic complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer (Abstract S3-03).
Related Videos
Harold J. Burstein, MD, PhD, on Adjuvant Endocrine Therapy: Expert Perspective
Harold J. Burstein, MD, PhD, from Dana-Farber Cancer Institute, gives an update on the duration of adjuvant endocrine therapy and offers his expert views on putting the research data ...
Joseph A. Sparano, MD, on Early-Stage Breast Cancer: Findings on the Tumor Microenvironment
Joseph A. Sparano, MD, of the Montefiore Medical Center, discusses the tumor microenvironment of metastasis score and its association with early distant recurrence in HR-positive, HER...
Lisa A. Carey, MD, on SABCS Meeting Highlights: Expert Perspective
Lisa A. Carey, MD, of the University of North Carolina, discusses a session she moderated on key data presented at SABCS, and gives her expert views on putting the research data into ...
Monica Morrow, MD: Brinker Award Lecture Summary on Changing Paradigms in Local Therapy of Breast Cancer
Monica Morrow, MD, of Memorial Sloan Kettering Cancer Center, recognized at this year’s meeting for scientific distinction in clinical research, summarizes her Brinker Award lecture o...
Patricia A. Ganz, MD: Aromatase Inhibitors Data Review
Patricia A. Ganz, MD, of the UCLA Jonsson Comprehensive Cancer Center, summarizes two studies on using duloxetine for aromatase inhibitor–associated musculoskeletal symptoms, and arom...
